Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Alnylam Pharmaceuticals To Present HELIOS-B Phase 3 Study Results Of Vutrisiran At ESC Congress 2024; Announces Topline Results Demonstrating Significant Reduction In Mortality And Cardiovascular Events

Author: Benzinga Newsdesk | August 07, 2024 08:14am

Company To Host Conference Call And Investor Webcast On August 30, 2024

Posted In: ALNY